ESLA Profile
Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company specializing in the development of innovative T-cell therapies aimed at treating both blood cancers and solid tumors. The company is focused on harnessing the power of the immune system to create targeted and effective treatments for various forms of cancer. Its research is centered on developing advanced therapies that leverage T-cell technology to address significant unmet needs in oncology.
Among Estrella’s lead product candidates is EB103, which is being investigated for the treatment of diffuse large B-cell lymphoma (DLBCL). This therapy is currently in the preclinical trial phase and represents a promising approach to targeting this aggressive form of blood cancer. Another key candidate, EB104, is designed to address diffuse large B-cell lymphoma as well as acute lymphoblastic leukemia (ALL), aiming to provide novel treatment options for these challenging hematological malignancies.
Estrella Immunopharma has established a strategic collaborative partnership with Imugene Limited, focusing on the development of combined therapies for solid tumors. This collaboration involves the use of Imugene's CF33-CD19t product candidate in conjunction with Estrella's EB103. The partnership aims to enhance therapeutic efficacy through a synergistic approach, combining different mechanisms of action to improve treatment outcomes for patients with solid tumors.
Headquartered in Emeryville, California, Estrella Immunopharma is at the forefront of developing next-generation immunotherapies. The company's commitment to advancing T-cell therapy reflects its dedication to addressing critical gaps in cancer treatment. By pursuing innovative approaches and strategic collaborations, Estrella Immunopharma seeks to bring transformative therapies to market, ultimately improving the prognosis for patients with difficult-to-treat cancers.
|
